Cai De Jin

Dr. Cai De Jin

Affiliated Hospital of Zunyi Medical University
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2014 in Platelets
Verified
Journal Article
Closed access
LGLong Zhe Guo
Long Zhe Guo
MKMoo Hyun Kim
Moo Hyun Kim
Cai De JinCai De Jin
Cai De Jin
JLJu Yeong Lee
Ju Yeong Lee
SYSo Jeong Yi
So Jeong Yi
TPTae-Ho Park
Tae-Ho Park
The novel antiplatelet agent ticagrelor has been demonstrated to exert a faster and more powerful inhibition of platelet aggregation in comparison to clopidogrel in coronary artery disease patients. However, a ticagrelor dose of 90 mg twice daily might not be suitable for patients of East Asian ethnicity, and has not been fully investigated. The aim of this study was to assess the effects of low loading doses (LD, 90 mg) and maintenance doses (MD, 90 mg daily) of ticagrelor in comparison to clopidogrel (600 mg LD, 75 mg daily MD) in healthy Korean volunteers. Twelve subjects were randomized into two groups, receiving either clopidogrel (600 mg LD, followed by 75 mg MD daily for 5 days) or ticagrelor (90 mg LD, followed by 90 mg MD daily for 5 days). Following a 2-week washout period, the treatments were switched between the groups. Three platelet function assessment methods which included light transmission aggregometry (LTA), the VerifyNow assay and multiple electrode platelet aggregometry (MEA) were then used to serially measure platelet function at various time points (baseline, 0.5, 2, 6, 24, 26, 120 and 122 h). The mean IPA to 10 µM ADP in the ticagrelor group was significantly higher than that for the clopidogrel group at the 0.5, 2, 6, 26 and 122 h time points (p ≤ 0.001). However, there was no significant difference between the two groups at the 24- and 120-hour time points (p > 0.05). The assay results produced by the other two platelet function tests (VerifyNow and MEA) were similar to those obtained by LTA. The low loading and maintenance doses of ticagrelor (90 mg LD, 90 mg daily MD) cause a more rapid and potent inhibition of platelet function when compared to clopidogrel (600 mg LD and 75 mg MD). Additionally, at the lowest value of platelet inhibition strength, oral once-daily administration of ticagrelor was no less efficacious than clopidogrel at the 24- and 120-hour time points. Due to a large diurnal variation occurring with a single daily dose, a lower dose twice-daily could be a better option for patients of East Asian ethnicity.

1 January 2015 in Circulation Journal
Verified
Journal Article
Closed access
YLYoung Seok Lee
Young Seok Lee
Cai De JinCai De Jin
Cai De Jin
MKMoo Hyun Kim
Moo Hyun Kim
LGLong Zhe Guo
Long Zhe Guo
YCYoung-Rak Cho
Young-Rak Cho
YKYoung Dae Kim
Young Dae Kim
There is insufficient data on the efficacy of prasugrel and ticagrelor in Korean patients with ST-segment elevation myocardial infarction (STEMI). I n the current double-blind, prospective pilot study, 39 patients with STEMI undergoing primary percutaneous coronary intervention were randomized to receive prasugrel 60 mg loading dose (LD) followed by 10 mg daily maintenance dose (n=19), or ticagrelor 180 mg LD followed by 90 mg twice daily maintenance dose (n=20). We assessed platelet reactivity with the VerifyNow and Vasodilator-Stimulated Phosphoprotein (VASP) P2Y12 assays. Compared to baseline platelet reactivity, both prasugrel and ticagrelor groups achieved similar and significantly lower P2Y12 reaction units (PRU) (259 [IQR: 230 to 281] vs. 28 [12 to 55] for prasugrel; 261 [196 to 286] vs. 43 [11 to 61] for ticagrelor), and platelet reactivity indexes (PRI) (51.2% [39.3 to 61.3] vs. 8.1% [6.1 to 14.7] for prasugrel; 47.5% [38.4 to 50.4] vs. 11.2% [7.1 to 15.5] for ticagrelor, all P values <0.001) at 48 h post-LD. Most patients had low platelet reactivity with 95% PRU values <85 and 82% with PRI <16%. Both prasugrel and ticagrelor were effective for platelet inhibition in Korean STEMI patients with almost no patients exhibiting high platelet reactivity at 48 h after the LD. Our finding of a high number of patients with very low platelet reactivity deserves further studies to assess the safety of the drugs (Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction Study, NCT02075125).

Verified
Journal Article
Open access
PDF file
Cai De JinCai De Jin
Cai De Jin
MKMoo Hyun Kim
Moo Hyun Kim
KSKai Song
Kai Song
XJXuan Jin
Xuan Jin
KLKwang Min Lee
Kwang Min Lee
MLMichael S. Lee
Michael S. Lee
East Asians treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) generally experience more intense platelet inhibitory responses resulting in an increased risk of major bleeding. Whether a half-dose de-escalation strategy improves the net clinical benefit in Korean patients with acute coronary syndrome (ACS) remains uncertain. A total of 120 patients were pragmatically randomized to either prasugrel (n = 39, 60 mg loading dose (LD)/10 mg maintenance dose (MD)), ticagrelor (n = 40, 180 mg LD/90 mg MD), or clopidogrel (n = 41, 600 mg LD/75 mg MD) followed by a half-dose reduction at 1 month, or conventional dose 75 mg clopidogrel. The primary endpoint was the incidence of optimal platelet reactivity (OPR), defined as a P2Y12 reaction unit (PRU) value between 85 and 208 (by VerifyNow) at 3 months. Ticagrelor treatment achieved a significantly lower PRU compared with prasugrel and clopidogrel (31.0 ± 34.5 vs. 93.2 ± 57.1 vs. 153.1 ± 69.4), resulting in the lowest rate of OPR (12.5% vs. 48.7% vs. 63.4%). At 9 months, the minor bleeding was significantly higher with potent P2Y12 inhibitors than with clopidogrel (31.6% vs. 12.2%; HR, 2.93; 95% CI, 1.12–7.75). Only a few patients experienced ischemic complications. In Korean ACS patients, a de-escalation strategy with half-dose ticagrelor and prasugrel from standard dose increased the OPR rate significantly. Half-dose ticagrelor had a lower OPR rate and greater platelet inhibition compared with half-dose prasugrel as well as conventional-dose clopidogrel. Optimal dose reduction strategies for potent P2Y12 inhibitors require further investigation to balance safety and efficacy.

6 July 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
EKEun-Ju Kang
Eun-Ju Kang
MKMoo Hyun Kim
Moo Hyun Kim
Cai De JinCai De Jin
Cai De Jin
JSJeongmin Seo
Jeongmin Seo
DKDong Won Kim
Dong Won Kim
YYYeonyee Elizabeth Yoon
Yeonyee Elizabeth Yoon

13 February 2016 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
SASoe Hee Ann
Soe Hee Ann
Cai De JinCai De Jin
Cai De Jin
GSGillian Balbir Singh
Gillian Balbir Singh
KLKyung Hun Lim
Kyung Hun Lim
JCJae-Wook Chung
Jae-Wook Chung
ESEun-seok Shin
Eun-seok Shin

5 March 2014 in Journal of Interventional Cardiology
Verified
Journal Article
Closed access
PDF file
SASoe Hee Ann
Soe Hee Ann
JCJae‐Wook Chung
Jae‐Wook Chung
Cai De JinCai De Jin
Cai De Jin
JLJun Ho Lee
Jun Ho Lee
JKJong Min Kim
Jong Min Kim
ESEun-seok Shin
Eun-seok Shin